Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3342346 | Autoimmunity Reviews | 2008 | 7 Pages |
Abstract
Immunoglobulins (Igs) that bind amyloid β peptide (Aβ) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze Aβ. Hydrolysis of peripheral Aβ by the IgMs may induce increased Aβ release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced Aβ aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hiroaki Taguchi, Stephanie Planque, Yasuhiro Nishiyama, Paul Szabo, Marc E. Weksler, Robert P. Friedland, Sudhir Paul,